Bosnia and Herzegovina vs Egypt: Statin use vs. average non-HDL cholesterol levels
Bosnia and Herzegovina
3.3
in 2018
Egypt
3.3
in 2018
Bosnia and Herzegovina rank
95th
Egypt rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Bosnia and Herzegovina
- Egypt
How they compare
Bosnia and Herzegovina currently reports 3.3 against 3.3 in Egypt, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Bosnia and Herzegovina ahead.
Bosnia and Herzegovina ranks 95th and Egypt ranks 95th of 191 countries.
Across the 4 decades both report, Bosnia and Herzegovina averaged higher in 2 and Egypt in 2.
Head to head by decade
| Decade | Bosnia and Herzegovina | Egypt | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.68 | 3.41 | 0.27 | Bosnia and Herzegovina |
| 1990s | 3.7 | 3.56 | 0.14 | Bosnia and Herzegovina |
| 2000s | 3.55 | 3.58 | 0.03 | Egypt |
| 2010s | 3.36 | 3.41 | 0.0556 | Egypt |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Bosnia and Herzegovina or Egypt?
- Bosnia and Herzegovina, at 3.3 against 3.3 in Egypt as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Bosnia and Herzegovina and Egypt?
- 0, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Egypt?
- 39 years are reported by both, from 1980 to 2018.
- How do Bosnia and Herzegovina and Egypt rank globally for statin use vs. average non-hdl cholesterol levels?
- Bosnia and Herzegovina ranks 95th and Egypt ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.